News

Shionogi Inc Signs Agreement to Expand Its Portfolio With Acquisition of Nine Marketed Products from Victory Pharma

Jul 18 2011

FLORHAM PARK, New Jersey—Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced that it has entered into an agreement to acquire all currently marketed products from Victory Pharma, Inc., including seven treatments for pain and two for infectious diseases.
The products, which are all approved by the Food and Drug Administration (FDA), will be marketed by Shionogi’s existing sales force. The terms of the deal stipulate a cash payment in the amount of $118 million at closing with up to $9 million in additional milestone payments. The transaction is currently
subject to expiration of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended, and to other customary closing conditions. It is anticipated that the transaction may close as early as July 26, 2011.

“Shionogi Inc. is committed to providing patients with innovative products to treat pain and infectious diseases, and the addition of these products to our current portfolio will provide us with an immediate presence in this market as we continue to develop related products in our pipeline,” said John Keller,
Ph.D., President and Chief Executive Officer of Shionogi Inc. “This acquisition will further establish Shionogi in the U.S., particularly in these key therapeutic areas, while generating growth in the short term and building a platform for future products in the longer term.”  At the centerpiece of the announcement is Victory’s lead product NAPRELAN®, a once-daily controlledrelease formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID). Additionally, Shionogi Inc. will obtain marketing rights for pain management products Rybix® ODT, XODOL®, Fexmid® 7.5mg, Dolgic® Plus, Zebutal® and Magnacet® as well as anti-infectives Moxatag® and Keflex®.

About Victory Pharma, Inc.
Founded in 2004, Victory Pharma, Inc. is a privately-held specialty pharmaceutical company headquartered in San Diego, California that has focused on acquiring, developing and marketing products to treat pain and related conditions. Further information is available at www.victorypharma.com.
NAPRELAN® is a trademark of Elan Corporation, plc.

About Shionogi & Co., Ltd.
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer.  Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi.com.

Contact:
Shionogi Inc.
Yoshimasa Kyokawa
Telephone: +1-973-307-3448
[email protected]